Skip to content

Multicenter and Prospective Clinical Registry Study of Autoimmune Encephalitis in China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02561260
Enrollment
400
Registered
2015-09-28
Start date
2015-05-31
Completion date
Unknown
Last updated
2015-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Encephlitis in China

Brief summary

In recent years, more and more previously thought to be unknown encephalitis was found to be a specific antigen associated encephalitis,but because of the lack of recognition in the clinic, usually been misdiagnosed as other causes of encephalitis. Therefore, it is urgent to establish a database of autoimmune encephalitis in Chinese population. The prospective clinical trial of atutoimmune encephalitis in China, by screening the autoimmune encephalitis associated antibody and summarizing the cases analysis, in order to provide evidence for clinical diagnosis and treatment of autoimmune encephalitis.

Interventions

None listed

Sponsors

Beijing Tiantan Hospital
CollaboratorOTHER
Xuanwu Hospital, Beijing
CollaboratorOTHER
Peking Union Medical College Hospital
CollaboratorOTHER
Beijing Children's Hospital
CollaboratorOTHER
Beijing Tongren Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
No

Inclusion criteria

1. Older than 6 months. 2. Encephalopathy symptoms (change of mental state and consciousness level) persist for more than 24 hours; 3. At least one or more clinical features of the followings: fever, epilepsy, focal neurological deficiency symptoms, changes in CSF(cerebrospinal fluid inflammatory), changes in EEG (electroencephalogram), radiographic abnormalities; 4. Clinical suspected encephalitis, but conventional detected methods cannot make etiology clear. 5. Signed the informed consent.

Exclusion criteria

1. Infants less than 6 months; 2. The metabolic encephalopathy; 3. Infectious encephalitis with clear pathogen clinically, referring the specific pathogenic microorganisms, including: bacteria, virus, fungus, parasite, spirochete and so on; 4. Non-infectious encephalitis with clear diagnosis clinically, including: multiple sclerosis, neuromyelitis optic, acute disseminated encephalomyelitis and so on.

Design outcomes

Primary

MeasureTime frame
death30days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026